Radiopharma company Nuclidium Secures $105 Million in Latest Funding Round

Radiopharma company Nuclidium secured $105 million in its latest funding round, adding another data point to the Enterprise Technology funding market.

Radiopharma company Nuclidium Raises $105 million in Funding

Radiopharma company Nuclidium is a Enterprise Technology company.

Investors Behind the Funding

The round was backed by undisclosed investors. Funding Intelligence tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Radiopharma company Nuclidium operates in Enterprise Technology. Radiopharma company Nuclidium's Unknown round shows investors are still backing enterprise technology platforms with real scale narratives. At $105M, the deal suggests buyers want category leaders that can turn AI, automation, or workflow leverage into durable enterprise demand.

Strategic Use of Funds

The company is expected to use the new capital to expand its platform, support customers, and continue scaling in Enterprise Technology.

Looking Ahead

Radiopharma company Nuclidium raises 105 million Swiss francs in funding round

Source reference: original announcement/article.